SLC5A2 and chronic kidney disease: Among adults with incident type 2 diabetes, utilization of GLP‐1 receptor agonists and SGLT‐2 inhibitors increased in parallel with evolving guidelines that prioritized the management of CVD and CKD comorbidities.